Sugi Predict

Sugi Predict / Targets / AADAC

AADAC

Arylacetamide deacetylase · P22760 · AADAC on Sugi Atlas →

1,891 patent compounds predicted against AADAC, 1,242 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Flutamide Flutamide (SCHEMBL3934) 1.00 1/20
Flutamide Flutamide (SCHEMBL1461845) 1.00 1/20
Flutamide Flutamide (SCHEMBL679388) 0.93 1/20
Flutamide Flutamide (SCHEMBL7104567) 0.90 1/20
Flutamide Flutamide (SCHEMBL1028216) 0.86 1/20
SCHEMBL655232 SCHEMBL655232 0.83 1/20
SCHEMBL3180031 SCHEMBL3180031 0.83 1/20
SCHEMBL11512367 SCHEMBL11512367 0.83 1/20
SCHEMBL11512254 SCHEMBL11512254 0.81 1/20
SCHEMBL12731497 SCHEMBL12731497 0.80 1/20
SCHEMBL4256244 SCHEMBL4256244 0.80 1/20
SCHEMBL4256246 SCHEMBL4256246 0.80 1/20
SCHEMBL8407363 SCHEMBL8407363 0.79 1/20
Flutamide Flutamide (SCHEMBL8937698) 0.79 1/20
SCHEMBL12932289 SCHEMBL12932289 0.78 1/20
SCHEMBL8410451 SCHEMBL8410451 0.77 1/20
SCHEMBL10437874 SCHEMBL10437874 0.77 1/20
SCHEMBL11511325 SCHEMBL11511325 0.77 1/20
SCHEMBL12475045 SCHEMBL12475045 0.77 1/20
SCHEMBL11305506 SCHEMBL11305506 0.76 1/20

Clinical trials — most relevant to AADAC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Voronistat in Pediatric Patients With Drug Resistant Epilepsy PHASE2UNKNOWN
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension PHASE2NOT_YET_RECRUITING
Vorinostat in Children PHASE1/PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) PHASE1/PHASE2UNKNOWN
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies PHASE2COMPLETED
Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer PHASE2WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia PHASE1COMPLETED
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma PHASE1COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma EARLY_PHASE1WITHDRAWN
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AADAC binder may also engage these)

ProteinNameSimilarity
Q0P5B7 — 1.000 Q0P5B7 →
Q7M370 — 0.996 Q7M370 →
Q9QZH8 — 0.993 Q9QZH8 →
Q99PG0 — 0.993 Q99PG0 →
Q6P093 — 0.992 Q6P093 →
Q5VUY2 — 0.985 Q5VUY2 →
A2A7Z8 — 0.984 A2A7Z8 →
Q8BM81 — 0.982 Q8BM81 →
P04058 — 0.974 P04058 →
P07692 — 0.973 P07692 →
Q63010 — 0.972 Q63010 →
Q8IUS5 — 0.971 Q8IUS5 →
Q6IRP4 — 0.971 Q6IRP4 →
Q9CQF9 — 0.970 Q9CQF9 →
Q25489 — 0.970 Q25489 →
Q8MZR5 — 0.970 Q8MZR5 →
Q28262 — 0.970 Q28262 →
P78898 — 0.970 P78898 →
Q5VUY0 — 0.970 Q5VUY0 →
Q64176 — 0.970 Q64176 →
Q7Z5M8 — 0.969 Q7Z5M8 →
Q7L211 — 0.969 Q7L211 →
Q80UX8 — 0.969 Q80UX8 →
P87172 — 0.968 P87172 →
P0DKC5 — 0.968 P0DKC5 →
P0DKC6 — 0.968 P0DKC6 →
Q5ZJL8 — 0.968 Q5ZJL8 →
Q5RFJ3 — 0.968 Q5RFJ3 →
Q5PPS7 — 0.967 Q5PPS7 →
Q9H3G5 — 0.967 Q9H3G5 →